Monday, February 28, 2022 Daily Archives

eBook: Sensors — Process Analytics for Modern Biopharmaceutical Workflows

by , and

To achieve quality by design in biopharmaceutical production, manufacturers need tools that can ensure the stability of critical process parameters (CPPs) and other performance indicators related to product critical quality attributes (CQAs). Over the past couple of decades, sophisticated process analytical technologies (PATs) have emerged to address such needs. Offerings are now abounding for single-purpose sensors that measure temperature, pressure, pH, glucose, protein concentration, or dissolved oxygen. New in-line formats are enabling such instruments to provide data in real time,…

February 28, 2022

Biocon buying Viatris biosimilar biz in $3.3bn deal

by

Indian drugmaker Biocon will add a portfolio of biosimilars – estimated to bring in $875 million in 2022 sales – through the planned acquisition. The deal, announced Sunday, will see Biocon Biologics pay up to $3.335 billion, made up of $2.335 billion in cash and $1 billion in Compulsorily Convertible Preference Shares (CCPS), for its partner Viatris’ biosimilars division. Viatris will own at least 12.9% of Biocon Biologics once the deal goes through. Kiran Mazumdar-Shaw, Biocon’s executive chair, described the…

February 28, 2022

CRL forecasts manufacturing business growth in 2022

by

Revenue from Charles River Laboratories’ manufacturing business increased significantly in 2021 thanks to increased demand and the positive impact of acquisitions. Charles River Laboratories’ (CRL’s) revenue for 2021 increased 21.1% to $3.54 billion. Its discovery and safety assessment unit made the biggest contribution, bringing in $2.11 billion which is 14.7% more than in 2020. Revenue from research models and services climbed 20.9% to $690.4 million. However, in terms of growth, CRL’s manufacturing and related services business gained the most ground.…

February 28, 2022

PerkinElmer teams with CRG for diabetes gene therapy

by

PerkinElmer acquisition Sirion Biotech has partnered with the Center for Genomic Regulation (CRG) in Barcelona, Spain to develop adeno-associated virus (AAV) vectors for type 1 and 2 diabetes. Viral vector-based gene therapy firm Sirion (acquired by PerkinElmer in June 2021) will use its AAV technology platform alongside international biomedical research center CRG’s knowledge of genetic regulatory mechanisms. The goal of the partnership is to create AAV vectors that target specific pancreatic cell types and contain payloads that express therapeutic genes…

February 28, 2022

Cytiva to build first oligo FlexFactory for Chinese CDMO

by

Chinese drugmaker General Biol has chosen Cytiva’s single-use Flex-Factory platform to support oligonucleotide production. The deal, of which financial details have not been disclosed, sees Cytiva provide General Biol with its integrated FlexFactory single-use  platform. This includes an OligoProcess nucleic acid synthesis system, ÄKTA Process explosion-proof purification system, and a Uniflux explosion-proof tangential flow ultrafiltration system. “A FlexFactory is a biomanufacturing platform that supports different types of manufacturing processes,†a spokesperson for Cytiva told us. “It is configurable with respect…

February 28, 2022

Polyplus adds DNA services with e-Zyvec buy

by

Through the acquisition of DNA design and production services firm e-Zyvec, Polyplus will expand its plasmid DNA vector engineering offerings. The French biotech would not disclose any financial details of the deal but told BioProcess Insider the acquisition “critical to execute Polyplus’ portfolio diversification strategy by acquiring plasmid DNA (pDNA) engineering capability that will provide synergies to our customers in terms of process efficiency.†Polyplus claims to be the market leader in transfection reagents for gene therapy viral vector manufacturing and through…

February 28, 2022